An observational study in Body Dysmorphic Disorders, sponsored by Massachusetts General Hospital. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-09-21.
Sponsored by Massachusetts General Hospital · Observational
Body dysmorphic disorder (BDD) is associated with high risk for suicide attempts (22-28%) and substance use disorders (49%), underscoring the importance of accurate, real-time risk detection in BDD. This study aims to use smartphone-based digital phenotyping to develop and validate unobtrusive, time-sensitive, and ecologically valid measures of key risk factors for suicide and substance misuse in BDD: negative affect states. As next steps, this research can be extended to detect risk transdiagnostically, with the goal of enabling just-in-time interventions to target suicide and substance misuse across psychiatric illnesses.
56 studies on the registry are indexed under Body Dysmorphic Disorders; 11 are open to participants now.
This study's enrollment of 87 is below the median of 150 across 11 observational studies indexed under Body Dysmorphic Disorders.
Browse Body Dysmorphic Disorders studies →Massachusetts General Hospital is the lead sponsor of 2,586 studies on the registry; 447 are open to participants now.
Of its 222 completed or terminated interventional studies of FDA-regulated products, 168 (76%) have results posted.
Counted across the registry records on this site, refreshed daily.
Adults with a current primary diagnosis of body dysmorphic disorder (BDD) within the U.S.
Inclusion Criteria:
Adults with a current primary diagnosis of body dysmorphic disorder (BDD)
Other: None, observational study only (no interventions)
None, observational study only (no interventions)
Self-reported anxiety intensity, rated from 1 (very slightly or not at all) to 5 (extremely)
Ecological momentary assessment (EMA) of anxiety intensity, where higher scores indicated more severe anxiety.
Time frame: 3 months
Self-reported shame intensity, based on Positive and negative affect scale (PANAS) shame item, rated from 1 (very slightly or not at all) to 5 (extremely)
Ecological momentary assessment (EMA) of shame intensity, where higher scores indicate more severe shame.
Time frame: 3 months
Self-reported negative affect intensity, based on Positive and negative affect scale (PANAS) negative affect items (averaged), rated from 1 (very slightly or not at all) to 5 (extremely)
Ecological momentary assessment (EMA)-rated general negative affect intensity, where higher scores indicate more severe negative affect.
Time frame: 3 months
Ran from Jul 2020 to primary completion in Apr 2023, 33 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Massachusetts General Hospital →